Stocks Health care INTS
NASDAQ · Health careIntensity Therapeutics, Inc. (INTS)
It posted a net loss of $11.2M. At June 30, 2026 it held $9.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
What Intensity Therapeutics, Inc. does
Intensity Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker INTS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$11.6M | -$8.56 | n/a |
| 2024 | n/a | -$16.3M | -$29.24 | n/a |
| 2023 | n/a | -$10.5M | -$34.49 | n/a |
| 2023 | n/a | -$7.6M | -$55.48 | n/a |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Intensity Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 11, 2026
- August 11, 2026
- July 8, 2026
- June 16, 2026
- May 7, 2026
- May 7, 2026
- April 30, 2026
- April 30, 2026Additional proxy material DEFA14A
- April 30, 2026Proxy statement DEF 14A
- March 27, 2026
Insider trades
What the people running Intensity Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 30, 2026 | Talamo JosephChief Financial Officer | Received as pay | 1,093 | $3.8K |
| June 30, 2026 | Wesolowski John MPrincipal Accounting Officer | Received as pay | 3,688 | $12.9K |
Who owns INTS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
2 insiders reported holding 9,341 shares in total, about $35.5K at the last price.
| Holder | Shares |
|---|---|
| Wesolowski John MPrincipal Accounting Officer | 7,102 |
| Talamo JosephChief Financial Officer | 2,239 |
Questions about INTS
What does Intensity Therapeutics, Inc. do?
Intensity Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker INTS.
Is Intensity Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $11.2M.
When did Intensity Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026.
Similar companies
Compare INTS with
Follow INTS
Get an email when Intensity Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow INTS: get an email when it filesWhere the numbers come from
Financial figures are the values Intensity Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.